- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03243552
Proof of Mechanism Study for the Treatment of Social Anhedonia in ASD (ACEP4)
Proof of Mecahism Study for the Treatment of Social Anhedonia in ASD
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Participants will comprise two groups: 1) 56 (male and female) adolescents and young adults likely to meet inclusion/exclusion confirmed by study assessment who will be outpatients, ages 13 to 30 years, inclusive; and 2) 18 (male and female) healthy adolescents and young adults without any history of significant psychiatric disorders or treatment, who will be ambulatory, and will reflect the racial, ethnic, and socio-economic composition of Los Angeles, and will be recruited without regard to gender, race, or ethnic background.
Healthy control adolescents (and parents) and young adults who meet all inclusion and exclusion criteria, will undergo a one-day 4-5 hour research evaluation of current functioning and behavior, cognitive function, including intellectual testing, urine drug screen, completion of questionnaires about possible psychological symptoms, perform brief tests to measure reward response, and complete a research Magnetic Resonance Imaging scan. Healthy control will not receive any interventions or medication.
All eligible ASD participants will be enrolled concurrently in a 16-week, structured, group-based, social skills training program (PEERS®). After screening evaluations, eligible subjects will undergo baseline MRI scanning and behavioral assessments (self- and parent-report measures, videotaped interaction) and then randomized in a blocked schedule to yield 1:1 L-DOPA: placebo assignment, before beginning weekly social skills training. Medication administration will begin simultaneously with social skills training, and subjects will be seen weekly for the 1st 8 weeks, then biweekly for the final 4 weeks for safety assessments, dose titration, and compliance checks. During the 16-week study period, primary behavioral assessments will be repeated at Week 8 and at end of study on Week 16. A second MRI scan will be obtained within + 4 days of last social skills session. A follow-up safety phone call to assess post-study condition will be performed 30 days after completion of double-blind. The rich set of behavioral observations obtained across the 16 weeks will allow the possible identification of early clinical efficacy changes associated with L-DOPA administration, which could add further support for investigating this mechanism in future studies. Results from the project should inform reseacher's understanding of determinants of social dysfunction in ASD and may support further investigation of treatments modulating central nervous system dopamine function as a therapeutic strategy to enhance social functioning in ASD.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Jenny T Cowen, PhD
- Phone Number: 310-825-6170
- Email: jcowen@mednet.ucla.edu
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- University of California, Los Angeles
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ages 13 - 30 years inclusive;
- meets diagnostic criteria for ASD by clinical evaluation and ADOS;
- estimated FS IQ >70; 4) English reading ability of 6th grade;
- ability to participate and complete protocol expectations (fMRI scan, testing) in the examining clinician's judgment; and
- planned enrollment and acceptance for the UCLA PEERS® adolescent or young adult social skills training program.
Exclusion Criteria:
- significant perceptual deficits;
- need for continuation or anticipated of use of prohibited dopamine-modifying medications (stimulants, antipsychotics);
- presence of serious behavioral comorbidity such as aggression, major depressive disorder requiring additional intervention, or self-injurious behavior, or current of past history of suspected psychotic disorder;
- history of tic disorder;
- presence of significant medical illness which may impact CNS function.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: L-DOPA versus Placebo
L-DOPA or placebo (1:1 randomization).
Dosing will begin at 25mg carbidopa/100mg L-DOPA in 3 divided doses, with a fixed-flexible titration schedule, allowing dose increases once per week of 100mg L-DOPA.
Maximum dose is 600mg/d.
|
Participants will be randomized in a blocked schedule to yield 1:1 L-DOPA: placebo assignment.
ASD participants will be enrolled concurrently in a 16-week manualized, structured, group-based, social skills training program (PEERS).
Other Names:
|
Experimental: Social Skills
All participants will receive 16-week manualized social skills training.
|
Participants will be randomized in a blocked schedule to yield 1:1 L-DOPA: placebo assignment.
ASD participants will be enrolled concurrently in a 16-week manualized, structured, group-based, social skills training program (PEERS).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in fMRI: Social Reward Task from Baseline to week 16 (4 months)
Time Frame: Baseline, week 16
|
BOLD Activation: VS, ACC, OFC, Amygdala, Hippocampus (same units of measure)
|
Baseline, week 16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change on Anticipatory and Consummatory Interpersonal Pleasure Scale Adolescent (ACIPS-A)
Time Frame: Baseline, week 8 (midpoint), week 16 (4 month/end of study)
|
Total Score (change in score by timepoint; before treatment, midpoint, end)
|
Baseline, week 8 (midpoint), week 16 (4 month/end of study)
|
Change on Anticipatory and Consummatory Interpersonal Pleasure Scale (ACIPS)
Time Frame: Baseline, week 8 (midpoint), week 16 (4 month/end of study)
|
Total Score (change in score by timepoint; before treatment, midpoint, end)
|
Baseline, week 8 (midpoint), week 16 (4 month/end of study)
|
Change on Child Behavior Checklist (CBCL)
Time Frame: Baseline, week 16 (4 month/end of study)
|
T Scores of Syndrome Scales for ages 18 or under
|
Baseline, week 16 (4 month/end of study)
|
Change on Youth Self Report (YSR)
Time Frame: Baseline, week 16 (4 month/end of study)
|
T Scores of Syndrome Scales for ages 18 or under
|
Baseline, week 16 (4 month/end of study)
|
Change on Adult Behavior Checklist (ABCL)
Time Frame: Baseline, week 16 (4 month/end of study)
|
T Scores of Syndrome Scales for ages 18 or over
|
Baseline, week 16 (4 month/end of study)
|
Change on SRS Self Report
Time Frame: Baseline, week 8 (midpoint), week 16 (4 month/end of study)
|
Social Anhedonia
|
Baseline, week 8 (midpoint), week 16 (4 month/end of study)
|
Change on SRS Parent Report
Time Frame: Baseline, week 8 (midpoint), week 16 (4 month/end of study)
|
Social Anhedonia
|
Baseline, week 8 (midpoint), week 16 (4 month/end of study)
|
change on Social Communication Interaction Test (SCIT)
Time Frame: Baseline, week 8 (midpoint), week 16 (4 month/end of study)
|
6 subscales and total score (0-30)
|
Baseline, week 8 (midpoint), week 16 (4 month/end of study)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: James T McCracken, MD, University of California, Los Angeles
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACEPIV
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ASD
-
Sohag UniversityCompleted
-
University Rovira i VirgiliCompletedADHD | Probiotics | ASD | MicrobiotaSpain
-
Xinhua Hospital, Shanghai Jiao Tong University...Not yet recruiting
-
Jian-Jun OuRecruiting
-
Chen LiRecruiting
-
Xinhua Hospital, Shanghai Jiao Tong University...TerminatedASD Accompanied by Moderate to Severe Gastrointestinal SymptomsChina
-
Xinhua Hospital, Shanghai Jiao Tong University...Unknown
-
Centre Hospitalier Universitaire, AmiensRecruitingFunctional Magnetic Resonance Imaging | ASD | Social Cognition | Eye Tracking | Joint AttentionFrance
-
University of California, Los AngelesCompletedChildren at Risk for ASDUnited States
-
Hebrew University of JerusalemUnknown
Clinical Trials on L-DOPA versus Placebo
-
Impel PharmaceuticalsCompletedParkinson's DiseaseAustralia
-
Assistance Publique - Hôpitaux de ParisCompleted
-
GlaxoSmithKlineCompletedParkinson DiseaseUnited States, Korea, Republic of, Estonia, Russian Federation, Slovakia, Argentina, Chile
-
Children's Hospital of PhiladelphiaAvailableInsulinoma | Beckwith-Wiedemann Syndrome | Congenital Hyperinsulinism (CHI)United States
-
Assistance Publique - Hôpitaux de ParisTerminatedThyroid Carcinoma | Thyroid Neoplasm | Medullary CarcinomaFrance
-
Merck Sharp & Dohme LLCCompletedBrain Diseases | Central Nervous System Diseases | Parkinson Disease | Movement Disorders | Neurodegenerative Diseases
-
Biotie Therapies Inc.CompletedParkinson's DiseaseUkraine, Argentina, Romania, Canada, United States, Chile
-
University Hospital, ToulouseFrench Parkinson AssociationCompletedParkinson's DiseaseFrance
-
Children's Hospital of PhiladelphiaUniversity of PennsylvaniaCompletedHyperinsulinism | Congenital Hyperinsulinism | Persistent Hyperinsulinemic Hypoglycemia of Infancy | CHI | PHHIUnited States
-
Molecular NeuroImagingCompletedParkinson's Disease